Analysis of Promyelocytic Leukemia in Human Embryonic Carcinoma Stem Cells During Retinoic Acid-Induced Neural Differentiation
- PMID: 28959333
- PMCID: PMC5492245
- DOI: 10.15171/ijb.1358
Analysis of Promyelocytic Leukemia in Human Embryonic Carcinoma Stem Cells During Retinoic Acid-Induced Neural Differentiation
Abstract
Background: Promyelocytic leukemia protein (PML) is a tumor suppressor protein that is involved in myeloid cell differentiation in response to retinoic acid (RA). In addition, RA acts as a natural morphogen in neural development.
Objectives: This study aimed to examine PML gene expression in different stages of in vitro neural differentiation of NT2 cells, and to investigate the possible role of PML in pluripotency and/or neural development.
Materials and methods: RA was used as a neural inducer for in vitro neural differentiation of NT2 cells. During this process PML mRNA and protein levels were assessed by quantitative real time RT-PCR (QRT-PCR) and Immunoblotting, respectively. Furthermore bisulfite sequencing PCR (BSP) was used to assess PML promoter methylation in NT2 cells and NT2 derived neuronal precursor cells (NT2.NPCs).
Results: QRT-PCR results showed that, PML had maximum expression with significant differences in NT2 derived neuronal precursor cells relative to NT2 cells and NT2 derived neural cells (NT2.NCs). Numerous isoforms of PML with different intensities appeared in immunoblots of pluripotent NT2 cells, NT2.NPCs, and NT2.NCs. Furthermore, the methylation of the PML promoter in NT2.NCs was 2.6 percent lower than NT2 cell.
Conclusions: The observed differences in PML expression in different cellular stages possibly could be attributed to the fact that PML in each developmental state might be involved in different cell signaling machinery and different functions. The appearance of different PML isoforms with more intensity in neural progenitor cells; may suggest apossible role for this protein in neural development.
Keywords: Pluripotent stem cells; Promyelocytic Leukemia; Retinoic acid.
Figures
Similar articles
-
Differentiation response of acute promyelocytic leukemia cells and PML/RARa leukemogenic activity studies by real-time RT-PCR.Mol Biotechnol. 2005 Jul;30(3):231-8. doi: 10.1385/mb:30:3:231. Mol Biotechnol. 2005. PMID: 15988048
-
Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.Oncogene. 1995 Jun 15;10(12):2307-14. Oncogene. 1995. PMID: 7784078
-
Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.Cancer Res. 2000 Apr 1;60(7):1824-9. Cancer Res. 2000. PMID: 10766166
-
Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.Curr Pharm Biotechnol. 2013;14(9):849-58. doi: 10.2174/1389201015666140113095812. Curr Pharm Biotechnol. 2013. PMID: 24433507 Review.
-
The molecular genetics of acute promyelocytic leukemia.Blood Rev. 1993 Jun;7(2):87-93. doi: 10.1016/s0268-960x(05)80018-9. Blood Rev. 1993. PMID: 8396481 Review.
References
-
- Freemont PS, Hanson IM, Trowsdale J. A novel gysteine-rich sequence motif. Cell. 1991;64(3):483–484. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources